Filing summary
Entity note: The supplied filing is Global Medical REIT Inc.’s Form 10-Q, not a filing for Chiron Real Estate Inc. This summary reflects the filing text provided.
Business context and reporting period
The unaudited report covers the quarter and six months ended June 30, 2022. Global Medical REIT acquires healthcare facilities and leases them primarily to physician groups and healthcare systems. At quarter-end, its portfolio comprised 114 facilities and approximately 4.7 million leasable square feet.
Financial performance and position
Amounts below are in millions of dollars unless stated otherwise.
- Second-quarter revenue: $33.7, up 19.2% from $28.3 a year earlier. Rental revenue was $33.7.
- Second-quarter net income: $3.8 versus $4.2; net income attributable to common stockholders was $2.2, or $0.03 per share, versus $2.6, or $0.04 per share. Net margin was approximately 11.4%, compared with 14.7%.
- Six-month revenue and net income: Revenue was $65.6 versus $55.6; net income was $8.1 versus $7.5. Common-stockholder income was $4.9, or $0.07 per share, compared with $4.3, or $0.08 per share. Net margin was approximately 12.4%, versus 13.5%.
- REIT operating measures: Second-quarter FFO and AFFO were $0.24 and $0.25 per share and unit, respectively, versus $0.22 and $0.23. Six-month FFO and AFFO were $0.47 and $0.49, versus $0.44 and $0.47. These are non-GAAP measures as defined by the company.
- Cash flow, six months: Operating activities provided $39.9, compared with $33.1. Investing used $102.4, mainly for property purchases; financing provided $63.9. Cash and restricted cash totaled $14.2 at June 30.
- Debt and equity: Total debt, net of issuance costs, was $659.7, up from $571.7 at December 31, 2021. Total equity was $649.1. The weighted-average debt rate was 3.14%, compared with 2.87% at year-end 2021; weighted-average debt term was 3.79 years.
- Liquidity and dividends: Cash and cash equivalents, excluding restricted cash, were $5.9. The company reported $123.3 of revolver availability as of August 1; after the subsequent credit-facility amendment, total unused capacity, including a new delayed-draw loan, was $273.3. Common dividends were $0.21 per share for Q2; preferred dividends accrue at 7.5% annually.
Material changes versus the prior comparable period
- Revenue growth primarily reflected facilities acquired after June 30, 2021 and full-period contributions from earlier acquisitions. Nine properties were acquired during the first half of 2022 for an aggregate contractual purchase price of $98.1 million.
- Operating expenses increased $2.7 million in Q2 and $4.4 million for the first half, mainly because of reimbursable property costs and expenses at gross-lease properties. Depreciation and amortization also increased with portfolio growth.
- Q2 interest expense rose $0.4 million year over year, mainly due to higher average borrowings. First-half interest expense increased slightly, by $0.1 million.
- Common shares outstanding increased to 65.5 million from 64.9 million at year-end 2021. The company raised $10.3 million gross through ATM share sales during the first half.
- Interest-rate swap fair value shifted from a net liability of $6.6 million at year-end to an asset of $16.6 million at June 30. The resulting first-half other comprehensive income was $23.2 million; this is not operating cash flow.
Outlook, commentary, risks, and unusual items
- No formal earnings guidance is provided. Management describes aging demographics, growth in outpatient care, and healthcare-provider consolidation as potential supportive trends.
- Management highlighted rising interest rates, competition for acquisitions, COVID-19 disruption, inflation and supply-chain pressures, and possible reductions in healthcare reimbursement as risks. The company estimated that a 100-basis-point increase in rates on its June 30 variable-rate debt would raise annual interest expense by approximately $2.6 million.
- On August 1, 2022, the company amended its credit facility: it added a $150 million delayed-draw term loan maturing in 2028, extended the revolver maturity to August 2026, and transitioned facility borrowings from LIBOR to SOFR. On August 2, it entered into swaps fixing the SOFR component on the new loan at 2.54%.
- In July 2022, the company sold a Germantown, Tennessee medical office building for $17.9 million gross proceeds and estimated a $6.8 million gain. This transaction was not classified as held for sale at June 30. Two further acquisitions closed after quarter-end; four others were under contract as of August 1. A buyer terminated a contract to acquire the Belpre, Ohio property in June.
- Capital improvement commitments were approximately $24.2 million, with up to $20.4 million potentially due over the next 12 months, subject to contingencies. Preferred stock, with a $77.6 million liquidation preference, became redeemable by the company beginning in September 2022; redemption is optional.
- The company stated it complied with credit-facility covenants at June 30. It reported no material litigation or material changes to the risk factors in its 2021 Form 10-K. Disclosure controls were assessed as effective.
Important facts for investors to verify
- Confirm the intended issuer: the provided filing identifies Global Medical REIT Inc., rather than Chiron Real Estate Inc.
- Review the acquisition pipeline, tenant credit and rent collections, and the status and economics of the Belpre disposition and other contracted transactions.
- Assess the impact of SOFR-based borrowing costs, hedge transitions, covenant headroom, and the availability and terms of the amended credit facility.
- Compare AFFO with common and preferred dividend obligations, and consider the company’s substantial property investment and capital-improvement requirements.
- Monitor tenant reimbursement and lease-cost recoveries, healthcare reimbursement trends, COVID-19 effects, and the company’s ability to fund growth without materially increasing debt or equity dilution.